Britannia Life Sciences Inc.
BLSIF
$0.06
$0.03100.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -60.46% | -- | 65.91% | 7.42% | -- |
| Total Depreciation and Amortization | 5.61% | -- | 4.55% | 5.61% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 87.23% | -- | -112.48% | -84.47% | -- |
| Change in Net Operating Assets | -1,461.08% | -- | -98.51% | -262.07% | -- |
| Cash from Operations | 86.01% | -- | -678.33% | -8,849.47% | -1,119.86% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -- | -5,184.13% | -186.83% | -- |
| Cash from Investing | -100.00% | -- | -5,184.13% | -186.83% | 5,724.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 97.63% | -- | -28.94% | -41.23% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 90.37% | -- | -115.54% | 94.32% | 56.10% |
| Foreign Exchange rate Adjustments | 112.24% | -- | -89.79% | -145.74% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.41% | -- | -2,440.59% | -144.76% | 1,737.14% |